The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Grant Entitled “Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis”
Doylestown, PA. April 3, 2020 – FCCDC is pleased to announce that it has been awarded a Phase I STTR grant from the National Eye Institute entitled “Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis” (1R41EY030391-01A1). The Principal Investigator is Professor Robert Ricciardi of the University of Pennsylvania.